Preclinical
After more than two decades of attempts to develop a universal influenza vaccine, the global COVID-19 pandemic intensified the need for a broader vaccine for both illnesses.
Experts from U.S. health regulatory agencies have announced plans to conduct a clinical trial to assess the safety and efficacy of TPOXX (tecovirimat) as an antiviral for monkeypox.
Marengo Therapeutics and Ipsen have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.
A study published this month in Science discusses data that may support a devious alter ego of T-cells present within colorectal cancers that appear to inhibit and promote tumor progression.
The announcement signals that the WHO now views the outbreak as significant enough that a coordinated global response is necessary to control it.
In a recent interview with BioSpace, Imagine Pharma CEO Ngoc Thai shared the vast potential posed by a polypeptide called IMG-1 to treat Type 1 diabetes.
Frontera Therapeutics closed on a Series B funding round worth $160 million and announced an IND approval by the FDA for rare genetic retinal disease
Avista Therapeutics inked a partnership deal with Swiss pharma giant Roche to develop AAV gene therapy vectors for eye diseases.
A multinational research collaboration has developed a new peptide dubbed “PATAS”, which appears to fix the metabolic abnormalities leading to type 2 diabetes (T2D).
Seelos Therapeutics announced in vitro data Thursday supporting its gene therapy, SLS-004. SLS-004 is intended for the treatment of dementia with Lewy bodies (DLB).
PRESS RELEASES